First mRNA Flu Vaccine Receives Backing from FDA Panel
· Telemundo McAllen (KTLM)
A new type of flu vaccine took a step closer to the U.S. market on Thursday after federal health advisors recommended approval for the first vaccine developed using the same mRNA technology that was crucial in ending the COVID-19 pandemic. The Food and Drug Administration (FDA) is evaluating Moderna's new injection, called mFlusiva, for older Americans ahead of the winter flu season. Moderna is seeking full approval for the vaccine for individuals aged 50 to 64, along with authorization for use in those aged 65 and older while conducting additional trials. The FDA's independent advisory committee reviewed Moderna's studies on the vaccine and unanimously voted that its benefits appear to outweigh any risks for both age groups. The FDA will consider this recommendation when making a final decision in early August. Tens of thousands of Americans die from influenza each year, with older adults among the most vulnerable. There are already several types of flu vaccines available in the U.S., including three specifically recommended for those aged 65 and older. However, vaccines made with mRNA technology—awarded the Nobel Prize—are produced more quickly than other types, which experts say could help if the constantly changing flu virus mutates in a way that suddenly requires new adjusted doses. 'Having this technology available puts us in a better position to be prepared for emerging strains in the future,' said Dr. Flor Muñoz-Rivas from Texas Children’s Hospital and one of the FDA advisors.
AI summary · Source: Telemundo McAllen (KTLM) →
